Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma Genetics
Researchers from R.E. Kavetsky Institute of Experimental Pathology report recent findings in adenocarcinoma genetics
March 23rd, 2008
A new study, 'Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia,' is now available. Researchers in Ukraine conducted a study "To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia. Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients." "Expression of 53, MDM2 and p14 ARF was evaluated by immunohistochemical method using respective monoclonal antibodies. High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers. On...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-23)
|
